前列腺癌治疗市场－全球产业规模、份额、趋势、机会及预测（按治疗、按最终用户、按地区及竞争细分，2020-2030 年）

2024 年全球前列腺癌治疗市场价值为 134.5 亿美元，预计到 2030 年将达到 212.3 亿美元，预测期内的复合年增长率为 8.05%。前列腺癌治疗市场正在经历显着增长，这得益于人们认识的提高、发病率的上升以及诊断和治疗技术的进步。由于前列腺癌仍然是男性中最常见的癌症之一，因此对针对该疾病各个阶段的有效治疗方案的需求日益增长。市场涵盖了各种各样的疗法，包括荷尔蒙疗法、化疗、免疫疗法和标靶疗法。其中，雄激素剥夺疗法继续发挥核心作用，而较新的标靶疗法和免疫疗法由于其能够提供更个人化和有效的护理而越来越受到关注。

例如，根据美国癌症协会的资料，前列腺癌在老年男性中最为常见，约 60% 的诊断发生在 65 岁及以上的人群中，而在 40 岁以下的男性中很少见。男性首次诊断的典型年龄在 67 岁左右。这对老龄化人口的重大影响推动了对前列腺癌治疗的需求。

关键市场驱动因素

摄护腺癌发生率上升

主要市场挑战

治疗费用高昂

解决成本障碍对于扩大全球治疗机会、改善医疗公平性以及确保前列腺癌治疗市场的可持续成长至关重要。

主要市场趋势

精准医疗和标靶治疗

目录

第一章：服务概述

• 市场定义
• 市场范围
  • 覆盖市场
  • 考虑学习的年限
  • 主要市场区隔

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球前列腺癌治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗方法（荷尔蒙疗法、化疗、免疫疗法、标靶治疗、其他）
  • 按最终使用者（医院、肿瘤诊所、门诊手术中心等）
  • 按地区
  • 按公司分类（2022 年）
• 市场地图
  • 按治疗
  • 按最终用户

第六章：北美摄护腺癌治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲摄护腺癌治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区前列腺癌治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第九章：南美洲摄护腺癌治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲前列腺癌治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 沙乌地阿拉伯非洲

第 11 章：市场动态

• 驱动程式
  • 摄护腺癌盛行率不断上升。
  • 采用新型筛检和诊断技术
  • 研发热潮
• 挑战
  • 癌症治疗费用高昂
  • 荷尔蒙治疗的副作用

第 12 章：市场趋势与发展

• 产品发布
• 併购
• 技术进步

第 13 章：临床试验分析

第 14 章：全球前列腺癌治疗市场：SWOT 分析

第 15 章：竞争格局

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi SA
• Ipsen Pharma
• Bayer AG
• AstraZeneca Plc
• Valeant Pharmaceuticals International, Inc.
• Merck & Co., Inc.
• Pfizer Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Prostate Cancer Therapeutics Market was valued at USD 13.45 billion in 2024 and is expected to reach USD 21.23 billion by 2030 with a CAGR of 8.05% during the forecast period. The prostate cancer therapeutics market is experiencing significant growth, driven by rising awareness, increasing incidence rates, and advancements in diagnostic and treatment technologies. As prostate cancer remains one of the most commonly diagnosed cancers in men, there is a growing demand for effective treatment options across all stages of the disease. The market encompasses a wide range of therapies, including hormone therapy, chemotherapy, immunotherapy, and targeted therapy. Among these, androgen deprivation therapy continues to play a central role, while newer targeted treatments and immunotherapies are gaining traction due to their ability to provide more personalized and effective care.

For instance, according to data from the American Cancer Society, prostate cancer is most prevalent in older men, with around 60% of diagnoses occurring in those aged 65 and above, while it is rare in men under 40. The typical age for a man's first diagnosis is around 67. This significant impact on an aging population drives the demand for prostate cancer therapeutics.

Key Market Drivers

Rising Prevalence of Prostate Cancer

The rising prevalence of prostate cancer is a significant driver propelling the growth of the prostate cancer therapeutics market. For instance, according to the Global Cancer Observatory's GLOBOCAN 2022 report, prostate cancer ranked 4th among all cancer types, with approximately 1.47 million new cases reported in 2022. This high incidence rate significantly increases the demand for effective treatment options, driving the growth of the prostate cancer therapeutics market. Also, November is globally recognized as Prostate Cancer Awareness Month, focusing on raising awareness for prostate cancer in men. In November 2024, Europa Uomo members in Hungary and Italy contributed to this cause by launching prostate cancer testing programs as part of the "Movember" campaign. Prostate cancer has become one of the most commonly diagnosed cancers among men worldwide, with its incidence steadily increasing, particularly in aging populations. As life expectancy rises globally, the number of men at risk for prostate cancer also grows, leading to higher diagnosis rates. This trend is especially pronounced in developed countries where healthcare systems are more likely to perform regular screenings, including prostate-specific antigen (PSA) testing, resulting in earlier and more frequent detection of the disease.

The lifestyle changes such as sedentary habits, poor diet, and obesity-factors known to increase the risk of prostate cancer-are becoming more prevalent across both developed and developing nations. As awareness about the disease improves, more individuals are seeking early screening and diagnosis, which in turn increases the number of patients requiring treatment. This surge in demand places pressure on the healthcare system and pharmaceutical companies to innovate and deliver more effective, accessible, and targeted therapies.

The increasing prevalence of prostate cancer not only intensifies the need for conventional hormone and chemotherapy treatments but also creates opportunities for emerging therapies such as immunotherapy and precision medicine. Pharmaceutical firms are accelerating their research efforts to address the rising patient burden with therapies that offer better efficacy, fewer side effects, and improved survival rates. Governments and healthcare organizations are allocating more resources to prostate cancer research, awareness campaigns, and treatment access, particularly in regions where healthcare infrastructure is evolving. As a result, the growing prevalence of prostate cancer is acting as a catalyst for innovation, investment, and market expansion, making it a central force shaping the future of prostate cancer therapeutics globally.

Key Market Challenges

High Treatment Costs

High treatment costs represent a significant barrier to the growth and accessibility of the prostate cancer therapeutics market. Advanced therapies, such as targeted treatments, immunotherapies, and radioligand therapies, often come with premium pricing due to complex development processes, high research and manufacturing costs, and stringent regulatory requirements. These elevated costs can limit access to cutting-edge treatments, particularly in low- and middle-income countries where healthcare funding is constrained and out-of-pocket expenditures are common. Even in high-income regions, the financial burden on healthcare systems and patients can be substantial, often leading to disparities in care based on socioeconomic status or insurance coverage.

The long-term nature of prostate cancer treatment also contributes to rising expenses. Many patients require ongoing therapy over several years, which can accumulate into a significant financial strain. This is further complicated when patients develop resistance to first-line treatments, necessitating the use of newer, often more expensive, second- or third-line therapies. The associated costs such as diagnostics, monitoring, hospitalization, and supportive care amplify the total financial burden.

High treatment costs can also affect adherence to therapy, as some patients may discontinue or delay treatment due to affordability issues. This can result in disease progression and higher downstream healthcare expenses. From a market perspective, pricing pressures and reimbursement challenges may hinder the adoption of innovative therapies, slowing market growth and limiting the return on investment for pharmaceutical companies.

Addressing the cost barrier will be essential for expanding global access, improving equity in care, and ensuring the sustainable growth of the prostate cancer therapeutics market.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies are playing an increasingly critical role in shaping the future of the prostate cancer therapeutics market. As the understanding of prostate cancer biology deepens, treatment strategies are shifting from a one-size-fits-all approach to more personalized interventions that are tailored to the genetic and molecular profiles of individual patients. This shift is enhancing treatment efficacy, reducing side effects, and improving patient outcomes. Targeted therapies, particularly androgen receptor signaling inhibitors and PARP inhibitors, are at the forefront of this transformation. These treatments are designed to interfere with specific biological pathways that drive cancer growth, offering greater precision than traditional hormone therapies or chemotherapy. For example, PARP inhibitors have shown significant promise in patients with BRCA1 or BRCA2 gene mutations, marking a major advancement in treating advanced or metastatic prostate cancer.

Precision medicine also supports the identification of biomarkers that help predict a patient's response to specific therapies, guiding clinicians in selecting the most effective treatment from the outset. This not only increases treatment success rates but also reduces the likelihood of adverse effects associated with ineffective therapies. The growing demand for targeted therapies has spurred increased investment in research and development, with numerous precision drugs currently in clinical trials. Regulatory bodies are responding by granting expedited approvals for breakthrough therapies, accelerating their entry into the market. As more patients and healthcare providers adopt precision medicine approaches, this trend is expected to drive innovation, improve patient stratification, and significantly expand the prostate cancer therapeutics market in the coming years.

Key Market Players

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Ipsen Pharma
• Bayer AG
• AstraZeneca Plc
• Valeant Pharmaceuticals International, Inc.
• Merck & Co., Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Therapeutics Market, By Treatment:

• Hormonal Therapy
• Immunotherapy
• Targeted Therapy
• Others

Prostate Cancer Therapeutics Market, By End User:

• Hospitals
• Specialized Clinics
• Ambulatory Surgical Centers
• Others

Prostate Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.

Available Customizations:

Global Prostate Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prostate Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 5.2.1.1. Hormonal Therapy
      • 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
      • 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
      • 5.2.1.1.3. Anti-Androgen
    • 5.2.1.2. Chemotherapy
      • 5.2.1.2.1. Taxotere
      • 5.2.1.2.2. Jevtana
    • 5.2.1.3. Immunotherapy
      • 5.2.1.3.1. Provenge
    • 5.2.1.4. Target Therapy
      • 5.2.1.4.1. Xofigo
  • 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By End User

6. North America Prostate Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Prostate Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Prostate Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Prostate Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. India Prostate Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. South America Prostate Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Prevalence of Prostate Cancer.
  • 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
  • 11.1.3. Surge in Research and Development
• 11.2. Challenges
  • 11.2.1. High Cost of Cancer Treatment
  • 11.2.2. Side Effects of Hormonal Treatment

12. Market Trends & Developments

• 12.1. Product Launches
• 12.2. Mergers & Acquisitions
• 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Prostate Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Johnson & Johnson Services, Inc.
• 15.2. Astellas Pharma Inc.
• 15.3. Eli Lilly and Company
• 15.4. Sanofi S.A.
• 15.5. Ipsen Pharma
• 15.6. Bayer AG
• 15.7. AstraZeneca Plc
• 15.8. Valeant Pharmaceuticals International, Inc.
• 15.9. Merck & Co., Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer